Skip to main content
. 2018 Nov 19;2018(11):CD012502. doi: 10.1002/14651858.CD012502.pub2

1.34. Analysis.

Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 34 Discontinuation due to adverse event.